

CURRICULUM VITAE

Must be typed and all sections must be completed

Full Name:	Last Name Bussoletti	First Name Andrea	Middle Initial AB	Date: 24 Feb 2016
Study Site Affiliation: UOSD Patologie Retiniche , Policlinico Tor Vergata				
Professional Mailing Address: andrea.bussoletti@ptvonline.it		Study Site Address: Policlino Tor Vergata, UOSD Patologie Retiniche, Viale Oxford , 81 00133 Rome, Italy		
Telephone: (0039) 338 1470340		Telephone: (0039) 06 - 20903575		
<u>Academic Qualifications (most current date first)</u>				
<u>Degree/Certification</u>		<u>Date (mmm/yyyy)</u>		<u>Institution, Count</u>
Residency in Ophthalmology		Sep/2005		Università degli studi di Roma , Tor Vergata
Bachelor's Degreee in Ortottica ed Ass. In Oftalmologia		Mar/2000		Università degli studi di Roma , Tor Vergata
<u>Current Position and Previous 4 Relevant Positions Including Academic Appointments (most current date first):</u>				
<u>Dates In Years</u>		<u>Title</u>		<u>Institution/Company, Country</u>
2000 – 2005		Key Operator for Refractive Surgery		Private practice for several Health Centers
<i>Since 2005:</i>		Assistant of Ophthalmology		Policlinico di Tor Vergata
<i>Since 2006: "Tutor for practice in ophthalmology diagnostic techniques" of the Degree Course for Orthoptist and Assistant of Ophthalmology "Tor Vergata" University.</i>				
<i>2006 -2010 Professor: "Diagnostic Techniques Integrated Course" of the Degree Course for Orthoptist and Assistant of Ophthalmology "Tor Vergata" University.</i>				
<i>2012 – 2015: "tutor for MASTER M.I.T.O. – MONITORING FOR INDIVIDUALIZED TREATMENT OPTIMIZATION in patient with Age related Macular Desease" .</i>				
<i>2012 – 2015: Member of "PROGETTO OLIMPO: Standard operative procedures for centers of diagnosis and treatment of retina deseases"</i>				
Brief Summary of Relevant Clinical Research Experience:				
2008 VIEW2 Study (Bayer) as BCVA examiner				
2010 GALILEO Study (Bayer) as BCVA examiner				

2010 OPH 1001 Study (Ophotech Corp) as BCVA examiner

2010 RETAIN Study (Novartis Pharmaceuticals) as BCVA examiner

2011 FOVEA Study (Sanofi) as BCVA examiner

2011 VIVID DME Study (Bayer) as BCVA examiner

2011 PRIDE Study (Novartis Pharmaceuticals) as BCVA examiner

2012 BRIGHTER Study (Novartis Pharmaceuticals) as BCVA examiner

2012 CRYSTAL Study (Novartis Pharmaceuticals) as BCVA examiner

2013 ALLERGAN 206207024 Study (Allergan) as BCVA examiner

2014 PROMETEUS Study (Novartis Pharmaceuticals) as BCVA examiner

2014 OLIMPIC Study (Novartis Pharmaceuticals) as BCVA examiner

2014 TWEYES Study (Novartis Pharmaceuticals) as BCVA examiner

2015 CHROMA Study (Roche Pharmaceuticals) as BCVA examiner

18 May 2012 Certification Good Clinical Practice (GCP) for Investigator TFS Academy

07 02 2015 Certification Good Clinical Practice (GCP) E- learning Training Novartis

11 02 2015 Certification Good Clinical Practice" Minimum Criteria for ICH E6 GCP Investigator Site Personnel Training, Identified by TransCelerate BioPharma Inc.

Certification for BCVA with : EMMES, CLINITRIAL, ETONWOOD, CERTIFEYED, EVICR

License/ID Number: NA

in State/Province/Country: NA

"I conducted clinical research according to CGP and I authorize the use of my personal data according to D.Lgs. n°196/2003".